Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 3.44
VRTX's Cash-to-Debt is ranked lower than
67% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. VRTX: 3.44 )
Ranked among companies with meaningful Cash-to-Debt only.
VRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.15  Med: 2.37 Max: 26.61
Current: 3.44
1.15
26.61
Equity-to-Asset 0.57
VRTX's Equity-to-Asset is ranked lower than
63% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VRTX: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
VRTX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.07  Med: 0.55 Max: 0.93
Current: 0.57
0.07
0.93
Debt-to-Equity 0.30
VRTX's Debt-to-Equity is ranked lower than
53% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. VRTX: 0.30 )
Ranked among companies with meaningful Debt-to-Equity only.
VRTX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.48 Max: 9.45
Current: 0.3
0.03
9.45
Debt-to-EBITDA 5.87
VRTX's Debt-to-EBITDA is ranked lower than
68% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. VRTX: 5.87 )
Ranked among companies with meaningful Debt-to-EBITDA only.
VRTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.01  Med: -0.47 Max: 11.14
Current: 5.87
-2.01
11.14
Interest Coverage 6.83
VRTX's Interest Coverage is ranked lower than
96% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VRTX: 6.83 )
Ranked among companies with meaningful Interest Coverage only.
VRTX' s Interest Coverage Range Over the Past 10 Years
Min: 0.14  Med: 4.56 Max: 6.83
Current: 6.83
0.14
6.83
Piotroski F-Score: 8
Altman Z-Score: 15.34
Beneish M-Score: -2.63
WACC vs ROIC
13.99%
56.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 15.78
VRTX's Operating Margin % is ranked higher than
74% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. VRTX: 15.78 )
Ranked among companies with meaningful Operating Margin % only.
VRTX' s Operating Margin % Range Over the Past 10 Years
Min: -581.79  Med: -28.97 Max: 15.78
Current: 15.78
-581.79
15.78
Net Margin % 10.59
VRTX's Net Margin % is ranked higher than
82% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. VRTX: 10.59 )
Ranked among companies with meaningful Net Margin % only.
VRTX' s Net Margin % Range Over the Past 10 Years
Min: -630.27  Med: -45.31 Max: 10.59
Current: 10.59
-630.27
10.59
ROE % 16.14
VRTX's ROE % is ranked higher than
90% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. VRTX: 16.14 )
Ranked among companies with meaningful ROE % only.
VRTX' s ROE % Range Over the Past 10 Years
Min: -180.27  Med: -46.5 Max: 16.53
Current: 16.14
-180.27
16.53
ROA % 8.30
VRTX's ROA % is ranked higher than
89% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. VRTX: 8.30 )
Ranked among companies with meaningful ROA % only.
VRTX' s ROA % Range Over the Past 10 Years
Min: -58.14  Med: -20.28 Max: 8.3
Current: 8.3
-58.14
8.3
ROC (Joel Greenblatt) % 5.66
VRTX's ROC (Joel Greenblatt) % is ranked higher than
84% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. VRTX: 5.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1092.55  Med: -80.37 Max: 95.5
Current: 5.66
-1092.55
95.5
3-Year Revenue Growth Rate 58.50
VRTX's 3-Year Revenue Growth Rate is ranked higher than
89% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. VRTX: 58.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VRTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.5  Med: 13 Max: 129.4
Current: 58.5
-32.5
129.4
GuruFocus has detected 1 Warning Sign with Vertex Pharmaceuticals Inc VRTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VRTX's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

VRTX Guru Trades in Q2 2017

Ray Dalio 18,673 sh (New)
Joel Greenblatt 182,515 sh (New)
Ken Fisher 5,946 sh (+14.06%)
Eaton Vance Worldwide Health Sciences Fund 180,739 sh (unchged)
George Soros Sold Out
Manning & Napier Advisors, Inc 1,631,126 sh (-7.55%)
Vanguard Health Care Fund 11,626,983 sh (-10.66%)
Pioneer Investments 1,326,757 sh (-12.65%)
David Carlson 230,000 sh (-14.81%)
Jim Simons 21,700 sh (-45.91%)
Steven Cohen 11,141 sh (-95.90%)
» More
Q3 2017

VRTX Guru Trades in Q3 2017

Louis Moore Bacon 25,000 sh (New)
Ron Baron 29,783 sh (New)
Caxton Associates 2,000 sh (New)
Steven Cohen 909,230 sh (+8061.12%)
Jim Simons 1,368,020 sh (+6204.24%)
David Carlson 230,000 sh (unchged)
Ray Dalio Sold Out
Pioneer Investments 1,271,676 sh (-4.15%)
Ken Fisher 4,984 sh (-16.18%)
Vanguard Health Care Fund 9,658,658 sh (-16.93%)
Joel Greenblatt 110,500 sh (-39.46%)
Manning & Napier Advisors, Inc 885,868 sh (-45.69%)
Eaton Vance Worldwide Health Sciences Fund 154,789 sh (-14.36%)
» More
Q4 2017

VRTX Guru Trades in Q4 2017

Paul Tudor Jones 10,416 sh (New)
Jim Simons 2,847,917 sh (+108.18%)
Ron Baron 43,371 sh (+45.62%)
Ken Fisher 5,089 sh (+2.11%)
Pioneer Investments 1,288,046 sh (+1.29%)
David Carlson 230,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 154,789 sh (unchged)
Louis Moore Bacon Sold Out
Caxton Associates Sold Out
Vanguard Health Care Fund 9,003,258 sh (-6.79%)
Steven Cohen 709,817 sh (-21.93%)
Joel Greenblatt 14,984 sh (-86.44%)
» More
Q1 2018

VRTX Guru Trades in Q1 2018

Ken Fisher 7,395 sh (+45.31%)
Spiros Segalas 1,887,126 sh (-5.04%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Add 45.31%$151.6 - $177.13 $ 155.67-5%7,395
Vanguard Health Care Fund 2017-12-31 Reduce -6.79%0.21%$137.28 - $155.55 $ 155.675%9,003,258
Ron Baron 2017-12-31 Add 45.62%0.01%$137.28 - $155.55 $ 155.675%43,371
Joel Greenblatt 2017-12-31 Reduce -86.44%0.22%$137.28 - $155.55 $ 155.675%14,984
Ken Fisher 2017-12-31 Add 2.11%$137.28 - $155.55 $ 155.675%5,089
Vanguard Health Care Fund 2017-09-30 Reduce -16.93%0.55%$128.23 - $166.11 $ 155.674%9,658,658
Joel Greenblatt 2017-09-30 Reduce -39.46%0.13%$128.23 - $166.11 $ 155.674%110,500
Ron Baron 2017-09-30 New Buy0.02%$128.23 - $166.11 $ 155.674%29,783
Ken Fisher 2017-09-30 Reduce -16.18%$128.23 - $166.11 $ 155.674%4,984
Vanguard Health Care Fund 2017-06-30 Reduce -10.66%0.34%$107.45 - $135.53 $ 155.6730%11,626,983
Joel Greenblatt 2017-06-30 New Buy0.33%$107.45 - $135.53 $ 155.6730%182,515
Ken Fisher 2017-06-30 Add 14.06%$107.45 - $135.53 $ 155.6730%5,946
George Soros 2017-06-30 Sold Out 0.01%$107.45 - $135.53 $ 155.6730%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:LSE:SHP, XKRX:068270, NAS:REGN, XKRX:207940, NAS:BIIB, ASX:CSL, NAS:ALXN, NAS:CELG, NAS:INCY, XMCE:GRF.P, NAS:NKTR, HKSE:01177, SZSE:002252, XBRU:UCB, OCSE:NZYM B, NAS:BMRN, NAS:ALNY, OCSE:GEN, NAS:BIVV, HKSE:02269 » details
Traded in other countries:VRTX.Austria, VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Headquarter Location:USA
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco and Orkambi for cystic fibrosis, and the company also has several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, and influenza.

Top Ranked Articles about Vertex Pharmaceuticals Inc

Spring Forecast: Stocks to Buy With Your Tax Refund Investing your tax refund: best buys for spring
The stock market has been off to a rough start in 2018, with many speculating about a potential crash or a bear market. On closer inspection, though, it seems clear that the market is simply undergoing a typical correction in the wake of an earlier bull market. This is a natural trend and part of stabilizing the market for further investment – and makes it safe for investors to start wondering what stocks are good contenders for spring investments. Read more...
Steven Cohen Takes Stake in Biotech Company Agenus Guru expands position in health care space
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed this week he established a 6.13% stake in Agenus Inc. (NASDAQ:AGEN) on Feb. 21. Read more...
Wall Street Mixed on Thursday Ralph Lauren also disappoints on North America sales
U.S. stocks advanced in pre-market trading on Thursday ahead of positive macroeconomic data that showed that productivity increased 1.2% in 2017, compared to a 0.1% drop last year. However, they then entered into red zone. Read more...
Weekly CFO Sells Highlight Alcoa, Vertex were recently sold by company insiders
According to GuruFocus Insider Data, the recent chief financial officer sells were: Alcoa Corp. (NYSE:AA) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Read more...
Analysts Take Action on Healthcare Stocks Bank of America/Merrill Lynch added Allergan and Vertex Pharmaceuticals to its top stocks list
Analysts took action on healthcare stocks, records show. Read more...
Weekly CFO Sells Highlight Recent sells from company CFOs
According to GuruFocus Insider Data, the recent CFO sells were: Allison Transmission Holdings Inc. (NYSE:ALSN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Read more...
Steven Cohen Boosts Stake in Radius Health Company has burgeoning treatment for osteoporosis
Investor Steven Cohen (Trades, Portfolio) took notice of fast-growing biopharmaceutical company Radius Health (NASDAQ:RDUS), boosting his holdings by 405.6% on Nov. 24, GuruFocus RealTime Picks reported. Read more...
Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global – Discovering Underlying Factors of Influence
Vanguard Sells Medtronic, Cigna in 2nd Quarter Largest sales of the most recent quarter
Vanguard Health Care Fund (Trades, Portfolio) owns a portfolio composed of 74 stocks with a total value of $46.532 billion. During the second quarter the guru sold shares in the following stocks: Read more...
Weekly CFO Sells Highlight Recent sales from company chief financial officers
According to GuruFocus Insider Data, the recent CFO sells were: Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Johnson & Johnson (NYSE:JNJ). Read more...

Ratios

vs
industry
vs
history
PE Ratio 148.26
VRTX's PE Ratio is ranked lower than
91% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. VRTX: 148.26 )
Ranked among companies with meaningful PE Ratio only.
VRTX' s PE Ratio Range Over the Past 10 Years
Min: 25.82  Med: 144.75 Max: 560.57
Current: 148.26
25.82
560.57
Forward PE Ratio 53.48
VRTX's Forward PE Ratio is ranked lower than
77% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. VRTX: 53.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 148.26
VRTX's PE Ratio without NRI is ranked lower than
91% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. VRTX: 148.26 )
Ranked among companies with meaningful PE Ratio without NRI only.
VRTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.82  Med: 149.48 Max: 560.57
Current: 148.26
25.82
560.57
Price-to-Owner-Earnings 292.06
VRTX's Price-to-Owner-Earnings is ranked lower than
93% of the 148 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. VRTX: 292.06 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VRTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.93  Med: 161.67 Max: 546.26
Current: 292.06
20.93
546.26
PB Ratio 19.43
VRTX's PB Ratio is ranked lower than
91% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. VRTX: 19.43 )
Ranked among companies with meaningful PB Ratio only.
VRTX' s PB Ratio Range Over the Past 10 Years
Min: 5.78  Med: 15.09 Max: 37.6
Current: 19.43
5.78
37.6
PS Ratio 15.75
VRTX's PS Ratio is ranked lower than
59% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VRTX: 15.75 )
Ranked among companies with meaningful PS Ratio only.
VRTX' s PS Ratio Range Over the Past 10 Years
Min: 4.47  Med: 17.67 Max: 79.6
Current: 15.75
4.47
79.6
Price-to-Free-Cash-Flow 66.95
VRTX's Price-to-Free-Cash-Flow is ranked lower than
84% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. VRTX: 66.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRTX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.84  Med: 68.02 Max: 1552.81
Current: 66.95
11.84
1552.81
Price-to-Operating-Cash-Flow 46.37
VRTX's Price-to-Operating-Cash-Flow is ranked lower than
71% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. VRTX: 46.37 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRTX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.94  Med: 50.2 Max: 242.49
Current: 46.37
11.94
242.49
EV-to-EBIT 912.75
VRTX's EV-to-EBIT is ranked lower than
96% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. VRTX: 912.75 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -929.4  Med: -10.4 Max: 1510.2
Current: 912.75
-929.4
1510.2
EV-to-EBITDA 370.03
VRTX's EV-to-EBITDA is ranked lower than
94% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. VRTX: 370.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1137.1  Med: -10.7 Max: 2184.4
Current: 370.03
-1137.1
2184.4
EV-to-Revenue 15.35
VRTX's EV-to-Revenue is ranked lower than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. VRTX: 15.35 )
Ranked among companies with meaningful EV-to-Revenue only.
VRTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.2  Med: 16.55 Max: 76.5
Current: 15.35
4.2
76.5
Current Ratio 3.28
VRTX's Current Ratio is ranked lower than
58% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. VRTX: 3.28 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 4.24 Max: 20.55
Current: 3.28
2.23
20.55
Quick Ratio 3.14
VRTX's Quick Ratio is ranked lower than
56% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. VRTX: 3.14 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 2.21  Med: 4.2 Max: 20.55
Current: 3.14
2.21
20.55
Days Inventory 122.56
VRTX's Days Inventory is ranked higher than
52% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. VRTX: 122.56 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 125.66 Max: 254.87
Current: 122.56
62.49
254.87
Days Sales Outstanding 41.26
VRTX's Days Sales Outstanding is ranked higher than
69% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. VRTX: 41.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 42.11 Max: 61.46
Current: 41.26
25.75
61.46
Days Payable 98.17
VRTX's Days Payable is ranked higher than
64% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. VRTX: 98.17 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 98.17  Med: 279.06 Max: 1204.41
Current: 98.17
98.17
1204.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
VRTX's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. VRTX: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.2  Med: -12.3 Max: -1.6
Current: -1.6
-23.2
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 68.88
VRTX's Price-to-Net-Cash is ranked lower than
94% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. VRTX: 68.88 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VRTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.24  Med: 23.7 Max: 224.15
Current: 68.88
4.24
224.15
Price-to-Net-Current-Asset-Value 34.83
VRTX's Price-to-Net-Current-Asset-Value is ranked lower than
91% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. VRTX: 34.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VRTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.68  Med: 10.03 Max: 199.11
Current: 34.83
2.68
199.11
Price-to-Tangible-Book 20.22
VRTX's Price-to-Tangible-Book is ranked lower than
87% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. VRTX: 20.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.44  Med: 8.81 Max: 75.31
Current: 20.22
2.44
75.31
Price-to-Intrinsic-Value-Projected-FCF 31.19
VRTX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
89% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. VRTX: 31.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRTX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 30.03  Med: 49.81 Max: 819.67
Current: 31.19
30.03
819.67
Price-to-Median-PS-Value 0.89
VRTX's Price-to-Median-PS-Value is ranked lower than
52% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. VRTX: 0.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.02 Max: 4.13
Current: 0.89
0.29
4.13
Price-to-Graham-Number 11.60
VRTX's Price-to-Graham-Number is ranked lower than
93% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. VRTX: 11.60 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VRTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 4.84  Med: 15.2 Max: 28.14
Current: 11.6
4.84
28.14
Earnings Yield (Greenblatt) % 0.11
VRTX's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. VRTX: 0.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.5  Med: -2.9 Max: 5.2
Current: 0.11
-26.5
5.2

More Statistics

Revenue (TTM) (Mil) $2,488.65
EPS (TTM) $ 1.05
Beta1.95
Volatility23.21%
52-Week Range $113.66 - 178.25
Shares Outstanding (Mil)254.88

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,791 3,451 4,400
EBIT (Mil $) 801 1,248 1,791
EBITDA (Mil $) 970 1,394 1,998
EPS ($) 3.14 4.82 7.31
EPS without NRI ($) 3.14 4.82 7.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
74.96%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}